Acura Pharmaceuticals has filed a patent for an abuse deterrent pharmaceutical composition. The composition includes a drug susceptible to abuse, a first acid soluble ingredient, a first buffering ingredient, and a delayed release buffering component. The patent claim specifies that the composition limits the effects of over-ingestion by including a drug susceptible to over-ingestion, a first acid soluble ingredient, a first buffering ingredient, and an ingredient for increasing gastric emptying time. GlobalData’s report on Acura Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Acura Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Acura Pharmaceuticals, nanoparticle drug conjugates was a key innovation area identified from patents. Acura Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Abuse deterrent pharmaceutical composition with delayed release buffering

Source: United States Patent and Trademark Office(USPTO). Credit: Acura Pharmaceuticals Inc

A recently filed patent (Publication Number: US20230158008A1) describes a pharmaceutical composition designed to limit the effects of over-ingestion of a drug. The composition includes several key ingredients to achieve this purpose.

The first claim of the patent describes the pharmaceutical composition, which includes a drug susceptible to over-ingestion, a first acid soluble ingredient, a first buffering ingredient, and an ingredient for increasing gastric emptying time. The first acid soluble ingredient can be calcium carbonate, a cationic copolymer, or a combination of both. The cationic copolymer may consist of dimethylaminoethyl methacrylate, butyl methacrylate, or methyl methacrylate. The first buffering ingredient can be calcium carbonate, sodium bicarbonate, magnesium oxide, tribasic sodium phosphate, or combinations thereof. The ingredient for increasing gastric emptying time can be a monosaccharide, a disaccharide, an oligosaccharide, an amino acid, a peptide, a protein, a monoglyceride, a diglyceride, or a triglyceride. Alternatively, it can be loperamide, diphenoxylate, atropine, difenoxin, an anticholinergic, an antidepressant, an opioid, an antidiarrheal drug, or a gastroparesis inducing drug.

The patent also claims that the composition may include a delayed release buffering component, which can consist of a second acid soluble ingredient, a second buffering ingredient, an enteric ingredient, and a sustained-release ingredient. The second acid soluble ingredient can be the same as the first acid soluble ingredient, and the second buffering ingredient can be the same as the first buffering ingredient. The enteric ingredient can be shellac, methyl acrylate-methacrylic acid copolymers, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, hypromellose acetate succinate, polyvinyl acetate phthalate, sodium alginate, or zein.

Furthermore, the composition may include an ingredient for decreasing gastric acid production, such as an H2-antagonist. The H2-antagonist can be present in an amount that is 10-50% of the lowest therapeutic dose of the H2 antagonist for reducing stomach acid secretion.

In addition to the composition, the patent also claims a dosage form comprising the described composition and a method of treating a disease alleviated by a drug susceptible to over-ingestion. The method involves administering the composition to a subject in need of treatment.

Overall, this patent describes a pharmaceutical composition and its various components that are designed to limit the effects of over-ingestion of a drug. The composition includes acid soluble ingredients, buffering ingredients, ingredients for increasing gastric emptying time, and potentially delayed release buffering components. It also suggests the use of an ingredient for decreasing gastric acid production and provides a dosage form and treatment method utilizing the composition.

To know more about GlobalData’s detailed insights on Acura Pharmaceuticals, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies